Share

January 2017; 4 (1) ArticleOpen Access

Effects of neuromyelitis optica–IgG at the blood–brain barrier in vitro

Yukio Takeshita, Birgit Obermeier, Anne C. Cotleur, Simona F. Spampinato, Fumitaka Shimizu, Erin Yamamoto, Yasuteru Sano, Thomas J. Kryzer, Vanda A. Lennon, Takashi Kanda, Richard M. Ransohoff
First published December 19, 2016, DOI: https://doi.org/10.1212/NXI.0000000000000311
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
2048

Share

Article Information

vol. 4 no. 1 e311
DOI: 
https://doi.org/10.1212/NXI.0000000000000311
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received August 6, 2016
  • Accepted in final form November 2, 2016
  • First Published December 19, 2016.
Copyright & Usage: 
Copyright © 2016 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Yukio Takeshita, MD, PhD,
    2. Birgit Obermeier, PhD,
    3. Anne C. Cotleur, MS,
    4. Simona F. Spampinato, MD, PhD,
    5. Fumitaka Shimizu, MD, PhD,
    6. Erin Yamamoto, BA,
    7. Yasuteru Sano, MD, PhD,
    8. Thomas J. Kryzer, AS,
    9. Vanda A. Lennon, MD,
    10. Takashi Kanda, MD, PhD and
    11. Richard M. Ransohoff, MD
  1. Yukio Takeshita, MD, PhD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Birgit Obermeier, PhD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. I am now employee of Biogen (Postdoctoral Scientist, for 2 years), but was affiliated with the Cleveland Clinic at the time the study was performed and I have no conflicts to declare.

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Anne C. Cotleur, MS,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. 1. Biogen, Senior Supervisor, 2years

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. 1. Employee at Biogen Nov 2014-present (myself)

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Simona F. Spampinato, MD, PhD,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Fumitaka Shimizu, MD, PhD,
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Biogen, postdoctoral scientist, 1 years 10 month(2014.11- 2016.8)

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Erin Yamamoto, BA,
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Yasuteru Sano, MD, PhD,
    8. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Thomas J. Kryzer, AS,
    9. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  9. Vanda A. Lennon, MD,
    10. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. Vanda Lennon receives royalties from RSR/Kronus for sale of aquaporin-4 autoantibody testing kits and for commercial aquaporin-4 autoantibody testing performed outside Mayo Clinic.

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NIH R01-NS065829,?CNS Demyelinating Autoimmunity Targeting Water Channel Complexes?. Principal Investigator: S.J. Pittock Co-Investigator: V.A. Lennon Years: 2010-2015

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License fee payments, Technology or Inventions:

    1. 1) RSR/Kronus for sale of aquaporin-4 autoantibody testing kits. 2) Non-Mayo sites performing “home brew” diagnostic testing for aquaporin-4 autoantibody.

    Royalty Payments, Technology or Inventions:

    1. Dr. Lennon has a potential financial interest in the technologies listed below: “Aquaporin-4 as an aid for cancer diagnosis”.

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  10. Takashi Kanda, MD, PhD and
    11. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Clinical and Experimental Neuroimmunology Editor-in- Chief 2010- Neuropathology, Editorial Advisory Board Member 2009-

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. Contract Grant Sponsor: Japan Society for the Promotion of Science - Tokyo Contract Grant Number: 25293203, 26670443

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  11. Richard M. Ransohoff, MD
    12. Scientific Advisory Boards:

    1. Chemocentryx

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. BiogenIdec, speaker's honoraria Novartis, speaker's honoraria

    Editorial Boards:

    1. Neurology; N2

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Employed at present by Biogen. Work reported in this paper was completed before I joined Biogen.

    Consultancies:

    1. Pfizer Teva

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Chemocentryx, sponsored research agreement Biogen, sponsored research agreement National MS Society

    Research Support, Government Entities:

    1. NIH: P50 NS38667 R01 NS32151 R01 NS74804 R21 NS74820 K24 NS51400

    Research Support, Academic Entities:

    1. Travel support and/or honoraria were provided for each of the following: Special Guest & Speaker Max-Planck Institute Retreat Ringberg Germany, 2009 Invited Plenary Speaker 1st Keystone Symposium on MS, Santa Fe New Mexico, 2009 Grand Rounds in Neurology, Johns Hopkins University, Baltimore, 2009 Keynote Lecture, Opening of Neuropathology Institute, Freiburg Germany, 2009 Plenary Lecture, Kick-off meeting for Neurodegeneration Research Center, Bonn, 2009 Invited Seminar, Institute for Research in Biomedicine, Bellinzona, Switzerland, 2009 Invited Speaker, FDA/NYAS Conference: ?Cytokine Therapies?, New York, 2009 Invited External Speaker ?Annual Japanese MS Workshop? Kyushu Japan 2009 Visiting Professor, Dept of Neurology, Kyushu University, Fukuoka, Japan, 2009 Consultant, Nature ?Landscape? editorial meeting on Neuroimmunology, 2009 Invited Seminar, GSK Hammersmith Hospital, London, 2009 Invited Speaker 12th International Symposium “Signaling at the BBB”, London, England, 2009 Co-organizer/Speaker ?Chemokines and Chemokine Receptors in the CNS?, Rome, 2009 Grand Rounds in Neurology, Ottawa General Hospital, Ontario, Canada, 2009 Invited Speaker, Keystone Symposium ?Alzheimer?s Disease?, Colorado, 2010 NIH EUREKA Review IRGs, 2008-2010 Invited Speaker, ASN annual meeting, Santa Fe, 2010 Invited Speaker, Nikolas Histiocytosis-X Symposium, Athens, Greece, 2010 Invited speaker, FOCIS 2010 Symposium ?Interventional Immunology?, Boston, 2010 Keynote Speaker, Neuroimmunology Symposium, Kyoto, Japan, 2010 Workshop Chair, International Congress of Immunology, Kobe, Japan 2010 Plenary Lecture, PACTRIMS, Bali, Indonesia, 2010 Symposium Organizer and Chair ANA annual meeting, San Francisco, CA, 2010 Workshop Chair, Special Interest Groups, ANA, San Francisco, CA, 2010 Invited Speaker, Theodor Kocher Institute, Bern, Switzerland, 2010 Invited Speaker/Session Chair, Cell Press Symposium “Inflammation in Disease”, Lisbon, 2010 Invited Speaker, Brazilian Society of Pharmacology 42nd Annual Meeting, Brazil, 2010 External Reviewer, DFG ?Centers of Excellence? Applications, Frankfurt, Germany, 2011 Invited Speaker, AAAS/Abelson Symposium ?Defeating AD?, Washington DC, 2011

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. SAB, Chemocentryx Employee, Biogen

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Neuroinflammation Research Center (Y.T., B.O., A.C.C., S.F.S., F.S., E.Y., R.M.R.), Lerner Research Institute, Cleveland Clinic, OH; Department of Neurology and Clinical Neuroscience (Y.S., T.K.), Yamaguchi University Graduate School of Medicine, Japan; and Department of Laboratory Medicine and Pathology (T.J.K., V.A.L.), Mayo Clinic, Rochester, MN. Y.T. and F.S. are currently affiliated with the Department of Neurology and Clinical Neuroscience, Yamaguchi University Graduate School of Medicine, Japan. B.O., A.C.C., and R.M.R. are currently affiliated with Neuroimmunology Research, Biogen, Cambridge, MA. S.F.S. is currently affiliated with the Department of Biomedical and Biotechnological Sciences, Section of Pharmacology, University of Catania, Italy.
  1. Correspondence to Dr. Ransohoff: richard.ransohoff{at}biogen.com
View Full Text

Article usage

Article usage: December 2016 to May 2022

AbstractFullPdfSource
Dec 201694915Highwire
Dec 2016095pmc
Jan 201746923196Highwire
Jan 2017016292pmc
Feb 20171191820Highwire
Feb 201706735pmc
Mar 2017791413Highwire
Mar 201707231pmc
Apr 201799716Highwire
Apr 201793662pmc
May 20175397Highwire
May 2017164658pmc
Jun 201750211Highwire
Jun 2017144555pmc
Jul 20173149Highwire
Jul 2017143235pmc
Aug 201744614Highwire
Aug 2017122525pmc
Sep 20172145Highwire
Sep 2017133031pmc
Oct 20172536Highwire
Oct 201792122pmc
Nov 201723211Highwire
Nov 201792627pmc
Dec 201702014Highwire
Jan 20183719Highwire
Feb 20185611Highwire
Mar 20184123Highwire
Apr 20183179Highwire
Apr 2018102324pmc
May 201851511Highwire
Jun 20181158Highwire
Jun 2018192033pmc
Jul 20182274Highwire
Aug 201833113Highwire
Aug 201873653pmc
Sep 20189299Highwire
Oct 201883310Highwire
Nov 20186165Highwire
Dec 20185275Highwire
Jan 20196188Highwire
Feb 201992215Highwire
Mar 201984116Highwire
Apr 201952213Highwire
May 2019114521Highwire
Jun 2019197424Highwire
Jul 2019126216Highwire
Aug 2019127814Highwire
Sep 201931917Highwire
Oct 201973219Highwire
Nov 201982116Highwire
Dec 2019114226Highwire
Jan 2020102925Highwire
Feb 202062128Highwire
Mar 202053122Highwire
Apr 202053219Highwire
May 202055946Highwire
Jun 202053725Highwire
Jul 202003225Highwire
Aug 202052616Highwire
Sep 20201610941Highwire
Oct 2020118631Highwire
Nov 202098469Highwire
Dec 2020206452Highwire
Jan 2021155136Highwire
Feb 202154925Highwire
Mar 2021148670Highwire
Apr 2021175431Highwire
May 202185029Highwire
Jun 202184025Highwire
Jul 202194337Highwire
Aug 202173221Highwire
Sep 2021114027Highwire
Oct 202197240Highwire
Nov 2021116230Highwire
Dec 2021106130Highwire
Jan 202243917Highwire
Feb 202294727Highwire
Mar 2022105233Highwire
Apr 202202211Highwire
May 202264123Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top

Topics Discussed

Alert Me

Advertisement